Lutathera Therapy

Peptide Receptor Radionuclide (Lutathera) Therapy

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription therapy used to treat adults with a special type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These tumors can be in the stomach, intestines or pancreas. This treatment is available at the Medical University of South Carolina (MUSC)-Health Charleston Campus in the Nuclear Medicine Theranostic Suite.

LUTATHERA® is given as an intravenous (IV) infusion with other medications. A full course of therapy is four doses of LUTATHERA ® Doses given 8-16 weeks apart. At the end of each treatment, a long-acting octreotide injection is given. Therapy plans vary depending on how your body responds to the treatment.

Patients referred for therapy should have gastroenteropancreatic neuroendocrine tumors with evidence of disease progression, recent DOTATATE imaging, and appropriate blood counts, renal function, and liver function. Requests for therapy will be reviewed by MUSC nuclear medicine physicians to determine treatment eligibility. Insurance eligibility will also be completed prior to scheduling.

Please contact RN Patient Care Coordinator Jenny Hill MSN, RN at 843-792-9626 to begin the referral process and to obtain the referral form.

Patient information and education can be found at the following link: https://www.lutathera.com/download-helpful-materials/